Expansion opportunities TD2 Oncology is actively expanding across continents and capabilities, including Europe expansion in 2024, collaboration with Minerva Imaging for radiopharmaceutical development, and multi-omics partnerships in Missouri. This indicates ongoing capacity growth and new service lines open to prospective clients needing translational, regulatory, imaging, and early clinical support.

Strategic partnerships Recent partnerships with Panome Bio and Minerva Imaging suggest a market strategy aimed at integrating multi-omics, imaging, regulatory, and translational services. Prospective customers with complex, multi-disciplinary oncology programs could benefit from a one-stop, integrated CRO partner capable of accelerating translational workflows.

Regional presence Growth signals include new Europe operations and the Arizona-based recognition as Bioscience Company of the Year, underscoring a strengthened regional footprint. This positions TD2 as a favorable option for sponsors seeking geographically strategic CROs for global trial execution and local regulatory navigation.

Leadership and expertise Leadership expansion and senior hires targeting strategic solutions, along with TD2’s heritage from TGen and omics-focused expertise, highlight capabilities in complex oncology programs. This can be leveraged to pitch high-value translational studies, biomarker-driven trials, and scientific advisory services to biotech and pharma clients.

Service breadth From preclinical through first-in-human and early-phase studies to regulatory guidance, TD2 offers end-to-end oncology development support, including radioligand therapy facilitation via partnerships. This breadth enables cross-selling opportunities across drug modalities, enabling clients to consolidate vendor relationships and accelerate timelines.